Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gossypol Acetate Combined With Bevacizumab and FOLFIRI as Second-Line Therapy for Metastatic Colorectal Cancer
NCT07337551Phase 2Not yet recruiting
- Sponsor
- Guiying Wang
- Start
- Feb 2026
- Primary completion
- Feb 2028
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of gossypol acetate in metastatic colorectal cancer (mCRC), sponsored by Guiying Wang. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
gossypol acetate
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT07337551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07337551.